neurotrophic signaling is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-06-26. Numbers and descriptions here follow the published literature rather than marketing material.
Published research covers ischemic stroke, traumatic brain injury, cognitive impairment, optic nerve conditions and attention-related measures. Much of the human evidence comes from small trials conducted in one country, which limits how far the results generalize. Animal models supply the larger share of the data, and effects seen in rodents do not transfer automatically to people. Reviews have noted that methodological reporting is often incomplete, making it difficult to pool results or compare treatment schedules across studies.
Pharmacokinetic accounts emphasize rapid breakdown. After intravenous dosing the intact peptide disappears from blood within minutes, and nasal delivery produces low but measurable concentrations. Metabolites rather than the parent molecule may account for part of the observed activity, although the relative contribution is unresolved. Dosing in the literature varies widely and no optimal schedule has been agreed. These gaps are regularly cited as a reason the findings have not produced broad clinical adoption beyond the original research setting.
Scientific literature on semax is unevenly distributed. A substantial share of published work originates from a small number of laboratories in Russia, while independent replication elsewhere is limited. Human data consist mostly of small trials with short follow-up, and several reported outcomes rely on subjective rating scales. Questions about how much intact peptide reaches the central nervous system after nasal administration, and how long it persists there, are still unresolved. The compound is best described as an active research subject rather than a settled pharmacological agent.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was derived from the ACTH(4-10) fragment, a short segment of adrenocorticotropic hormone that lacks the hormonal activity associated with the full-length peptide. Researchers at the Institute of Molecular Genetics in Moscow developed the compound during the 1980s. It has been registered as a pharmaceutical product in Russia and several neighbouring countries, where it is supplied as a nasal solution, and it is also sold internationally as a research chemical.
| Property | Value | Notes |
|---|---|---|
| Primary research models | Rodent studies | Largest share of published data |
| Reported markers | BDNF and NGF expression | Measured mainly in animal tissue |
| Common administration | Intranasal | Matches the registered formulation |
| Blood residence time | Minutes | Rapid enzymatic degradation |
| Evidence quality | Small trials, limited replication | Noted repeatedly in reviews |
Quality documentation for research-grade peptide usually includes a certificate of analysis stating purity, identity, and residual counterion content. Batch-to-batch variation in purity and salt form is a recognized issue, and comparisons across suppliers require attention to the exact counterion, for example acetate versus trifluoroacetate. Sequence verification by tandem mass spectrometry provides stronger evidence than a single mass measurement. For any study reporting biological results, the analytical method and the measured purity should be stated explicitly. Independent verification of supplier claims is considered good practice.
Semax is supplied as a lyophilized powder that appears white to off-white. It dissolves readily in water, phosphate-buffered saline, and other aqueous media, which simplifies preparation of working solutions for laboratory use. The nasal products registered in Russia are dilute aqueous solutions, typically around 0.1 percent peptide by weight. Organic solvents are rarely necessary and can complicate handling. Because the peptide is hygroscopic, weighing should be performed quickly and with minimal exposure to ambient humidity.
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.
Published research has focused mainly on neurological and cognitive endpoints in animal models, with proposed mechanisms involving brain-derived neurotrophic factor and related signalling pathways. A substantial share of the human data originates from a limited number of research groups, and independent replication in other countries remains sparse. Regulatory status reflects that distribution: the peptide is registered as a medicine in Russia and appears in some neighbouring markets, while elsewhere it is handled as a research chemical without approved therapeutic labelling. Questions about dose-response relationships, long-term effects, and comparability across studies are still open.
Lyophilised powder is normally kept at -20 °C in a desiccated container, with some suppliers recommending -80 °C for long-term archival storage. Repeated freeze-thaw cycles are the most common cause of avoidable loss, so aliquoting before freezing reduces variability between working sessions. Dissolved peptide is far less stable than the dry solid and is usually prepared fresh or held briefly at 4 °C. Aqueous solutions support both hydrolysis of the backbone and oxidation of the N-terminal methionine, and these two routes dominate degradation under ordinary laboratory conditions.
Identity and purity are confirmed with reversed-phase high-performance liquid chromatography, typically monitored at 214 nanometres where the peptide bond absorbs. Mass spectrometry, either electrospray or MALDI-TOF, verifies molecular mass against the theoretical value and detects truncation or adduct formation. Amino acid analysis and peptide mapping provide additional confirmation when required. The most frequently reported impurities are deletion sequences from incomplete coupling, methionine sulfoxide from oxidation, and dimeric species formed through non-covalent aggregation. Impurity profiles depend strongly on the synthesis and purification route chosen by the producer.
There is agreement in the research community that tau contributes strongly to dementia in Alzheimer's disease. Tauopathy occurs in over 30 diseases in addition to Alzheimer's disease. In addition, mutations of the gene for tau (MAPT) cause neurodegenerative disorders known as primary tauopathies, but these diseases occur in the absence of Aβ proteopathy. Current evidence thus favors abnormal Aβ as the prime mover of Alzheimer's disease. However, the Aβ hypothesis and tau hypothesis are not mutually exclusive, in that abnormalities of Aβ initiate the disease and tauopathy is required for its complete expression.
=== Refractory coeliac disease === About 1.5% of those with coeliac disease develop refractory coeliac disease (RCD), which is the persistence of symptoms of malabsorption and villous atrophy despite at least one year of the GFD. RCD has a high mortality and morbidity rate, is associated with more severe symptoms and is more common in older individuals (50<). Those with RCD are often referred to specialists and the diagnostic process usually includes monitoring compliance with the GFD, confirming the initial diagnoses of coeliac disease, and excluding alternative explanations for small intestine damage such as Crohn's disease, peptic duodenitis, small intestinal bacterial overgrowth, hypogammaglobulinemia, common variable immunodeficiency, autoimmune enteropathy, tropical sprue, collagenous sprue, and eosinophilic enteritis. There are two subtypes of RCD, type 1 and type 2. Biopsies of the duodenum and analysis of the intraepithelial lymphocytes in the duodenum are required to distinguish between the two types. Type 2 RCD is characterised by abnormal T cells in the small intestine; these findings are absent in type 1 RCD. In type 2 RCD, healthy lymphocytes are replaced by abnormal lymphocytes, increasing the risk of complications such as enteropathy-associated T-cell lymphoma (EATL), severe malabsorption, and ulcerative jejunoileitis, and results in poorer outcomes. Type 1 RCD is treated with steroids, azathioprine, and budesonide. The treatment of type 2 RCD is more complicated as it often does not improve with steroids, and azathioprine may increase the risk of EATL.
IUPAC organic nomenclature has three main parts: the substituents, carbon chain length, and chemical affix. The substituents are any functional groups tied to the main carbon chain. The main carbon chain is the longest possible continuous chain. The chemical affix denotes what type of molecule it is. For example, the ending ane conveys a single bonded carbon chain, as in "hexane" (C6H14). Another example of IUPAC organic nomenclature is cyclohexanol:
=== May === 1 May – The FDA trade union announces plans to mount a legal challenge against the UK government's Safety of Rwanda Act amid concerns it breaches international law. MSPs vote 70–58 to defeat a motion of no confidence in the Scottish Government. 2 May – Local elections take place for councils and mayors in England and police and crime commissioners in England and Wales. The 2024 Blackpool South by-election is also held on the same day. John Swinney is set to become the next SNP leader and first minister after Kate Forbes confirms she will not seek the party's leadership. 3 May – With 90% of council election results announced, the Conservatives have lost over 400 council seats, while Labour regains control of Hartlepool, Redditch, Rushmoor and Thurrock Councils. Ben Houchen wins the Tees Valley mayoral election, retaining the seat for the Conservatives, while Labour win mayoral elections in the East Midlands, North East and York and North Yorkshire. Chris Webb wins the 2024 Blackpool South by-election, with a 26% swing to Labour. 2024 Peterborough City Council election: At 18, Daisy Creedon-Blakemore becomes the UK's youngest councillor after winning a seat for Labour in Peterborough City Council's Fletton and Woodston ward. 4 May 2024 London mayoral election: Labour's Sadiq Khan secures a third term as Mayor of London with 44% of the vote, beating the Conservative Susan Hall on 33%. 2024 West Midlands mayoral election: Labour's Richard Parker narrowly defeats the Conservative incumbent Andy Street to become Mayor of the West Midlands.
The chemistry of plutonium was found to resemble uranium after a few months of initial study. Early research was continued at the secret Metallurgical Laboratory of the University of Chicago. On August 20, 1942, a trace quantity of this element was isolated and measured for the first time. About 50 micrograms of plutonium-239 combined with uranium and fission products was produced and only about 1 microgram was isolated. This procedure enabled chemists to determine the new element's atomic weight. On December 2, 1942, on a racket court under the west grandstand at the University of Chicago's Stagg Field, researchers headed by Enrico Fermi achieved the first self-sustaining chain reaction in a graphite and uranium pile known as CP-1. Using theoretical information garnered from the operation of CP-1, DuPont constructed an air-cooled experimental production reactor, known as X-10, and a pilot chemical separation facility at Oak Ridge. The separation facility, using methods developed by Glenn T. Seaborg and a team of researchers at the Met Lab, removed plutonium from uranium irradiated in the X-10 reactor. Information from CP-1 was also useful to Met Lab scientists designing the water-cooled plutonium production reactors for Hanford. Construction at the site began in mid-1943. In November 1943 some plutonium trifluoride was reduced to create the first sample of plutonium metal: a few micrograms of metallic beads. Enough plutonium was produced to make it the first synthetically made element to be visible with the unaided eye.
Sources: en.wikipedia.org
=== Distribution === Estradiol is rapidly distributed throughout the body, with a distribution phase of about 6 minutes following intravenous injection. Estradiol is taken up into cells via passive diffusion due to its lipophilicity. Due to binding to the ERs, estradiol is preferentially concentrated in tissues with the highest ER content. In animals, these tissues have included the uterus, vagina, mammary glands, pituitary gland, hypothalamus, other brain regions, adipose tissue, liver, and adrenal glands, among other tissues. In contrast to estradiol, due to its low affinities for the ERs, estrone is not accumulated in target tissues. Estradiol has been found to cross the blood–brain barrier in rhesus monkeys. The volume of distribution of estradiol has been found to be 0.85 to 1.17 L/kg. In another study however, its volume of distribution was only 0.082 ± 0.015 L/kg (4.8 L in women of average weight 58.4 kg). In terms of plasma protein binding, estradiol is bound loosely to albumin and tightly to SHBG, with approximately 97 to 98% of estradiol bound to plasma proteins. In the circulation, approximately 38% of estradiol is bound to SHBG and 60% is bound to albumin, with 2 to 3% free or unbound. However, with oral estradiol, there is an increase in hepatic SHBG production and hence SHBG levels (e.g., +50%), and this results in a relatively reduced fraction of free estradiol. As only free estradiol that is not bound to plasma proteins or SHBG is biologically active, this may reduce the potency of oral estradiol by some degree.
Serum levels of the C21 11-oxygenated steroids: 21-deoxycorticosterone, also known as 11β-hydroxyprogesterone (11OHP4) and 21-deoxycortisol (21dF), have been known to be elevated in both non-classical and classical forms of CAH, and liquid chromatography–mass spectrometry profiles that include these steroids have been proposed for clinical applications, including newborn screening. Classical CAH patients receiving glucocorticoid therapy had C19 11-oxygenated steroid serum levels that were elevated compared to healthy controls. In CAH patients with poor disease control, 11-oxygenated androgens remain elevated for longer than 17OHP, thus serving as a better biomarker for the effectiveness of the disease control. In males with CAH, 11-oxygenated androgen levels may indicate the presence of testicular adrenal rest tumors.
=== Measurement === Platelet concentration in the blood (i.e. platelet count), can be measured manually using a hemocytometer, or by placing blood in an automated platelet analyzer using particle counting, such as a Coulter counter or optical methods. Most common blood testing methods include platelet count in their measurements, usually reported as PLT. Platelet concentrations vary between individuals and over time, with the population average between 250,000 and 260,000 cells per mm3 (equivalent to per microliter), but the typical laboratory accepted normal range is between 150,000 and 400,000 cells per mm3 or 150–400 billion per liter.
== Further reading == Aarhus, R.; Aarhus, R (1995). "A Derivative of NADP Mobilizes Calcium Stores Insensitive to Inositol Trisphosphate and Cyclic ADP-ribose". Journal of Biological Chemistry. 270 (5): 2152–7. doi:10.1074/jbc.270.5.2152. PMID 7836444.
Plasmolysis is the contraction of cells within plants due to the loss of water through osmosis. In a hypertonic environment, the cell membrane peels off the cell wall and the vacuole collapses. These cells will eventually wilt and die unless the flow of water caused by osmosis can stop the contraction of the cell membrane.
Sources: en.wikipedia.org
The main proposal is modulation of neurotrophic factors such as brain-derived neurotrophic factor, supported largely by animal experiments. Receptor-level targets have not been firmly established. Most reviews describe the mechanism as only partially characterized.
The compound is registered as a medicine in Russia, so clinical work has concentrated there. Trials elsewhere are few and generally small. This geographic concentration is a recognized limitation in evidence reviews.
Some fraction may reach the central nervous system through olfactory pathways, and this is often cited as the rationale for the nasal route. The size of that fraction in humans is not well quantified. Blood concentrations after nasal dosing are low, which complicates measurement.
Semax is based on the ACTH(4-10) fragment, a seven-amino-acid segment of adrenocorticotropic hormone. The synthetic peptide retains the core sequence while removing regions associated with endocrine activity. This modification is intended to isolate effects on the nervous system.